1) Gorson KC, Allam G, Ropper AH:Chronic inflammatory demyelinating polyneuropathy:clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48(2):321-8
2) Joint Task Force of the EFNS and the PNS:European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2005;10(3):220-8
3) Koski CL:Therapy of CIDP and related immune-mediated neuropathies. Neurology 2002;59(Suppl 6):S22-7
4) Toyka KV, Gold R:The pathogenesis of CIDP:rationale for treatment with immunomodulatory agents. Neurology 2003;60(Suppl 3):S2-7
5) Dyck PJ, Daube J, O'Brien P, et al:Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314(8):461-5
6) Hahn AF, Bolton CF, Pillay N, et al:Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996;119:1055-66
7) Dyck PJ, Litchy WJ, Kratz KM, et al:A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36(6):838-45
8) Lieker I, Slowinski T, Harms L, et al:A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy. J Clin Apher 2017;32(6):486-93